Material safety data sheet: diamabrush lithium densifier
Material Safety Data Sheet Material Identity: DIAMABRUSH LITHIUM DENSIFIER
SECTION I · PRODUCT IDENTIFICATION Manufactured For: Emergency Phone: ChemTel 1-800-255-3924 HMIS Rating Information Phone: 800-321-7044 Date Prepared: February 26, 2014 Health: 1 Fire: 0 Reactivity: 0 SECTION II · HAZARDOUS INGREDIENTS CHEMICAL NAME CAS Number SECTION III · PHYSICAL and CHEMICAL PROPERTIES Boiling Point: None. Vapor Density (Air=1): N/D pH: >10 Volatile % (v): N/A Solubility in Water: Completely Specific Gravity (H2O=1): 1.11 Appearance/Odor: Clear Liquid / No odor Evaporation Rate (Water=1): N/D SECTION IV · FIRE FIGHTING MEASURES Flash Point: None. Extinguishing Media: Any means suitable to surrounding fire. Fire Fighting Procedures: Not combustible. Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full bunker gear. Fire and Explosion Hazards: None known or expected to occur. SECTION V · STABILITY AND REACTIVITY Stability: Stable under ordinary use conditions and use. Conditions to Avoid: N/D Incompatibility: N/D Hazardous Decomposition Products: Oxides of Carbon. Hazardous Polymerization: Will not occur. SECTION VI · STORAGE AND HANDLING Handling: Use precautions normally practiced in chemical handling. Follow all warning and precautions listed for this product. Storage: Store in a cool, dry well ventilated area away from heat. Always store in original properly labeled container. Material Safety Data Sheet Material Identity: DIAMABRUSH LITHIUM DENSIFIER
SECTION VII · HEALTH AND FIRST AID Eyes: Irritating to the eyes. Prolonged contact may result in tissue injury. Skin: May cause slight to moderate irritation. Repeated or prolonged contact can cause redness or irritation. Inhalation: Excessive inhalation may cause irritation of the nose, throat and respiratory tract. Ingestion: Large volumes of this product will cause irritation of the digestive tract accompanied by nausea, vomiting, and gastroenteritis. FIRST AID PROCEDURES: Eyes: Flush with large amounts of cool running water for at least 15 minutes. Seek medical attention if irritation persists. Skin: Wash skin with soap and water. If irritation persists seek medical attention. Inhalation: Remove to fresh air. Seek medical attention as symptoms warrant. Ingestion: DO NOT induce vomiting. Drink large amounts of water or milk. Obtain immediate medical attention. SECTION VIII · EXPOSURE CONTROLS / PERSONAL PROTECTION Eye Protection: Eye Protection if product contact is possible during mass transfers. Respiratory Protection: None required under normal use conditions. Ventilation: None required under normal use conditions. Protective Clothing: None required under normal use conditions. Chemical resistant gloves are recommended during mass transfers. SECTION IX · ACCIDENTAL RELEASE MEASURES Small Spill: Stop source of spill. Absorb on inert media and collect into suitable container. Large Spill: Plug source of spill. Salvage as much usable material as possible. Absorb on inert media and collect into suitable container. Waste Disposal Method: Follow local, state and federal regulations for disposal. SECTION X · TRANSPORTAION U.S. Department of Transportation (Domestic Road or Rail) Proper Shipping Name: Not Regulated by US DOT Hazard Class: UN/NA Number:
N/A= NOT APPLICABLE · N/E=NOT ESTABLISHED · N/D=NOT DETERMINED · <=LESS THAN · >=MORE THAN NOTICE: The information contained on this Material Safety Data Sheet is considered accurate as of the date of publication. It is not necessarily all-inclusive nor fully adequate in every circumstance. The suggestions should not be confused with, nor followed in violation of applicable laws, regulations, rules or insurance requirements. No warranty, express or implied, of merchantability, fitness, accuracy of data or the results to be obtained from the use thereof is made. The vendor assumes no responsibility for injury or damages resulting from the inappropriate use of this product.
Company: Cubist Pharmaceuticals, Inc. (CBST) Publication Date: November 17, 2003 Author: Eric Sharps, Ph.D. I have evaluated Cubist Pharmaceuticals, Inc. ("Cubist" or the "Company") for its suitability as a long investment. This report highlights the merits and risks for Cubist's future. Conclusion: Cubist is a third-tier biotechnology company likely to reach second-tier status in
Recreational Use of Bupropion (Wellbutrin ® ; Zyban ® ) (Wellbutrin ® ; Zyban ® ) is anand is used to treat a variety of Manufactured by GlaxoSmithKline, bupropion was first marketed as the anti-depressant Wellbutrin®, and later re-launched as Zyban®, a smoking-cessation aid. The two (2) drugs share an identical chemical structure and were differentiated only for marketing reason B